Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Summary

To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.

Timeline

Start

2008-02-05

Primary completion

2010-08-03

Completion

2014-07-17

Publications

• Park K, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. J Thorac Oncol. 2014 Oct;9(10):1523-31. doi: 10.1097/JTO.0000000000000275.

Drugs

Indications